Registration Options

Activity Dates: 05/16/2019 - 04/07/2022

Target Audience

This course is designed for pharmacists, nurse practitioners or other health care professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.

Session Summary

Tardive dyskinesia (TD) is an involuntary athetoid or choreiform movement commonly occurring in the tongue, lower face, and jaw, and/or extremities secondary to the treatment with antipsychotic medication for at least a few months. The underlying mechanism for the development of TD has not been definitively determined, which has led to difficulties in identifying treatment options. In April 2017, the Food and Drug Administration (FDA) approved the first two vesicular monoamine transporter 2 (VMAT2) inhibitor medications for the treatment of TD in adults. Nevertheless, TD remains a challenging medication-induced movement disorder for health care professionals to treat due to the ongoing need to prescribe antipsychotics for patients diagnosed with schizophrenia or other psychotic disorders, bipolar disorder, and treatment-resistant depression. Clinical psychiatric pharmacists are in a position to be able to not only assist in the identification of TD in patients prescribed antipsychotics but to also serve as a resource to other clinical providers in terms of strategies for both prevention and treatment of this movement disorder.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Sign in (or create a FREE account).
  • Register for this course.
  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date.
  • Complete the evaluation at the end of the activity.
  • If necessary, complete the post-test retest no later than the closing activity date.
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.

Participants in this course must complete an examination and achieve a score of 70% or greater. Successful completion of the course also requires the completion of a course evaluation. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at https://aapp.org/mycpnp/transcript/acpe.

Faculty Information and Disclosures

Steven Clark Stoner, PharmD, BCPP

View biographical information and disclosures

Learning Objectives

  1. Evaluate for the presence and severity of tardive dyskinesia (TD) based on commonly used rating scales.
  2. Assess the safety and efficacy of pharmacologic treatments for TD.
  3. Develop a treatment plan based on the safety and efficacy of the pharmacologic options to treat TD.

Continuing Education Credit and Disclosures

Activity Dates: 05/16/2019 - 04/07/2022
ACPE Contact Hours: 1
ACPE Number: 0284-0000-19-004-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This course provides 1.0 contact hour of application-based continuing education credit from CPNP approved programming.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.